Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 40Thoracic 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Brain Neoplasms 7Central Nervous System Neoplasms 6Breast Neoplasms 6Pancreatic Neoplasms 5Glioblastoma 5Ovarian Neoplasms 4Neoplasms 4Medulloblastoma 4Glioma 4Sarcoma 3Prostatic Neoplasms 3Osteosarcoma 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Neuroectodermal Tumors, Primitive 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Neoplasm Metastasis 2Multiple Myeloma 2Microphthalmia, Isolated, with Coloboma 5 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Esthesioneuroblastoma, Olfactory 2Diffuse Intrinsic Pontine Glioma 2

Interventions

Nivolumab 2Cisplatin 2Capecitabine 2tipifarnib 1olutasidenib 1entinostat 1Trastuzumab 1Thalidomide 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Leucovorin 1Irinotecan 1Ipilimumab 1Immunotherapy 1Gemcitabine 1Floxuridine 1Fentanyl 1Erlotinib Hydrochloride 1Epirubicin 1Drug Therapy 1Docetaxel 1Cetuximab 1Carboplatin 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Gemcitabine × CNS × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡